In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vical nets $31.7mm through FOPO

Executive Summary

Vical Inc. (DNA delivery technologies) has netted $31.7mm through the follow-on public offering of 15mm common shares at $2.25 each. The financing comes at a time when partner Sanofi announced the failure of Phase III Temusi to produce blood vessel growth in critical limb ischemia patients and another ally, AnGes, pulled the Japanese regulatory filing for Collategene, also for critical limb ischemia.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies